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TABLE 1 The Strengths and Limitations for the Japanese “þ10 for Your Health” Guideline
Strengths Limitations
1. Great motivator to initiate for the inactive 1. Not easy to sustain, as it tends to be overlooked as a daily routine
2. In line with increasing evidence of minimum amount of exercise,
such as 15-min walking or 5-min running
2. Signiﬁcant health beneﬁts from 10 min of walking has not been
scientiﬁcally documented; “þ15” may be better than “þ10”
3. Easy to start and to accomplish 3. May be too short to have aerobic effects—most of the 10 min
may be spent just in warming up
4. Most welcome by the elderly and disabled for this proposal 4. Younger adults gain less beneﬁts and have less enjoyment
5. Easy to squeeze into one’s schedule 5. Not enough time for socialization
6. Any exercise of 10 min duration counts 6. Confusion with nonexercise activity
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1156a no-brainer to expect a miracle, once one starts
to move “þ10” regularly. As Chinese philosopher
Lao-tzu said, “A journey of a thousand miles starts
with your single step,” (1) a 10-min dedicated brisk
walk is worth every bit of the 1,000 steps it
requires. Proof of these beneﬁts will be experienced
by the Japanese, who grabbed the low lying fruit of
10 min of exercise and declined to wait for the full
30-min prize, as if they knew “a bird in hand is
worth two in the bush”.*Chi Pang Wen, MD, DrPH
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of PCI or CABG in
Insulin-Treated Diabetic
PatientsReallyWorseThan
Non-Insulin-Treated Ones?In a recent issue of the Journal, Dangas et al. (1),
after analyzing 1,850 subjects from the FREEDOM(Comparison of Two Treatments for Multivessel
Coronary Artery Disease in Individuals With
Diabetes) trial, found that in patients with diabetes
and multivessel coronary artery disease, the rate of
major adverse cardiovascular events (death, myo-
cardial infarction, or stroke) is higher in patients
treated with insulin than it is in those not treated
with insulin. Their work is excellent, and the results
deserved to be considered given the large number of
patients with diabetes and multivessel coronary
artery disease who are being treated with insulin.
However, the investigators overlooked several issues
that might inﬂuence the results that we shall discuss
in the following text.
First, the patients were simply categorized into
insulin-treated diabetes mellitus (ITDM) and non-
ITDM according to their baseline use of insulin (either
alone or in combination with other oral antidiabetic
medication). However, the investigators ignored the
duration of insulin treatment and the dose of insulin.
Also, the kinds of oral antidiabetic medications were
unreported both in the ITDM and non-ITDM groups.
Second, the hemoglobin A1c was signiﬁcantly
higher in ITDM patients at baseline, which indicated
that ITDM patients were undertreated in the study.
But, why did this situation occur? Possibly because of
one of the following: poor self-monitoring of blood
glucose; worsening medical condition; insufﬁcient
insulin dose; or more severe insulin resistance.
Moreover, the quality of blood glucose control was
not reported either. From the original paper, we could
not assess the following queries: How many patients
discontinued insulin treatment? How often did the
hypoglycemia happen? What would the hemoglobin
A1c be within the 5-year follow-up?
Furthermore, the prevalence of peripheral neu-
ropathy was considerably low in the study compared
with prior studies (1,2). There were only 5.2% pe-
ripheral neuropathy in non-ITDM patients, and 14.3%
in ITDM patients. How do the investigators explain
this?
Ultimately, this was a post-hoc analysis based on
the FREEDOM trial. Though a multivariable Cox
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1157regression was used to adjust the confounding fac-
tors, the residual confounding still should not be
ignored because this method is not powerful enough
to fully adjust for unmeasured patient difference (3).
Falsiﬁcation hypotheses might be a more effective
statistical method in observation studies (4).
In other words, whether the rate of major adverse
cardiovascular events were really higher in patients
treated with insulin compared with the rates for those
not treatedwith insulin still needsmore rigorous trials.Xiao-jie Yang, MS
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